PEGylated Liposomal Nanocarriers in Cancer Therapy: Emerging Strategies and Clinical Prospects.
PEGylation has been shown to extend the circulatory lifetime, enhance drug deposition in tumors, and minimize off-target toxicity, and more effective design solutions should be employed, including stimuli-responsive liposomes and patient-tailored methods.